Greatly reduced risk of ebv reactivation in rituximab-experienced recipients of alemtuzumab-conditioned allogeneic hsct

HIGHLIGHTS

• who: D M Burns from the Incidence and kinetics of EBV reactivation and PTLD This study includes , adult patients undergoing first allo-HSCT with alemtuzumab TCD at University Hospital Birmingham, UKMedian follow-up was , months. Overall survival was, % at , year post transplant, with non-relapse mortality of, .9% at , days and, .5% at , year. Patient characteristics are summarised in Table, . Monitoring revealed a cumulative incidence of EBV reactivation (u2a7e, genomes/mL) of, % (95% confidence interval (CI), %) at , year (Figure, a). Furthermore, the cumulative incidence of high-level EBV reactivation (u2a7e, genomes/mL) was, % (CI, % have published the . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or E-mail:

  If you don't have an account, you can create one here.